<div id="readability-page-1"><p>Chardan Capital analyst Keay Nakae maintained a Buy rating on ProQR today and set a price target of $4.00.</p><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>According to TipRanks, Nakae is a 4-star analyst with an average return of <span>3.8%</span> and a 39.80% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arrowhead Pharmaceuticals, and ProQR.</p> <p>Currently, the analyst consensus on ProQR is a Strong Buy with an average price target of $6.50.</p></div>

SBIO

PRQR

<p>Chardan Capital analyst Keay Nakae has maintained a Buy rating on ProQR (PRQR) with a price target of $4.00. Nakae, a 4-star analyst with a 39.80% success rate, focuses on the Healthcare sector. The current analyst consensus on ProQR is a Strong Buy, with an average price target of $6.50.</p>

Tip Ranks

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

ProQR Therap

Invesco Biotechnology & Genome ETF

Chardan Capital Keeps Their Buy Rating on ProQR (PRQR)